

AIR FORCE HEALTH STUDY

**An Epidemiologic Investigation of
Health Effects in Air Force Personnel
Following Exposure to Herbicides**

May 1995

Volume II

1995 Followup Examination Results

**Epidemiologic Research Division
Armstrong Laboratory
Human Systems Center (AFMC)
Brooks Air Force Base, Texas 78235**

TABLE OF CONTENTS

VOLUME II

	Page
CHAPTER 10 NEOPLASIA ASSESSMENT	Page
INTRODUCTION	10-1
Background	10-1
Summary of Previous Analyses of the Air Force Health Study	10-3
1982 Baseline Study Summary Results	10-3
1985 Followup Study Summary Results	10-4
1987 Followup Study Summary Results	10-4
Serum Dioxin Analysis of 1987 Followup Study Summary Results	10-5
Parameters for the Neoplasia Assessment	10-5
Dependent Variables	10-5
Verified Medical Records Data	10-6
Laboratory Examination Data	10-7
Covariates	10-7
Statistical Methods	10-10
Longitudinal Analysis	10-16
RESULTS	10-16
Dependent Variable-Covariate Associations	10-16
Exposure Analysis	10-20
Verified Medical Records Variables	10-21
Skin Neoplasms	10-21
Malignant Skin Neoplasms	10-26
Benign Skin Neoplasms	10-31
Skin Neoplasms of Uncertain Behavior or Unspecified Nature	10-36
Basal Cell Carcinomas (All Sites Combined)	10-36
Basal Cell Carcinomas (Ear, Face, Head, and Neck)	10-45
Basal Cell Carcinomas (Trunk)	10-50
Basal Cell Carcinomas (Upper Extremities)	10-50
Basal Cell Carcinomas (Lower Extremities)	10-59
Squamous Cell Carcinomas	10-59
Nonmelanoma	10-68
Melanomas	10-73
Systemic Neoplasms	10-73
Malignant Systemic Neoplasms	10-73
Benign Systemic Neoplasms	10-82
Systemic Neoplasms of Uncertain Behavior or Unspecified Nature	10-91
Malignant Systemic Neoplasms (Eye, Ear, Face, Head, and Neck)	10-91
Malignant Systemic Neoplasms (Oral Cavity, Pharynx, and Larynx)	10-100
Malignant Systemic Neoplasms (Esophagus)	10-100
Malignant Systemic Neoplasms (Brain)	10-100

TABLE OF CONTENTS (Continued)

	Page
Malignant Systemic Neoplasms (Thymus, Heart, and Mediastinum)	10-111
Malignant Systemic Neoplasms (Thyroid Gland)	10-111
Malignant Systemic Neoplasms (Bronchus and Lung)	10-111
Malignant Systemic Neoplasms (Colon and Rectum)	10-124
Malignant Systemic Neoplasms (Kidney and Bladder)	10-124
Malignant Systemic Neoplasms (Prostate)	10-129
Malignant Systemic Neoplasms (Testicles)	10-129
Malignant Systemic Neoplasms (Ill-Defined Sites)	10-129
Malignant Systemic Neoplasms (Connective and Other Soft Tissue)	10-142
Carcinomas in Situ of the Penis, Other, and Unspecified Sites	10-142
Hodgkin's Disease	10-142
Leukemia	10-142
Non-Hodgkin's Lymphoma	10-142
Other Malignant Systemic Neoplasms of Lymphoid and Histiocytic Tissue	10-161
Multiple Myeloma	10-161
Skin or Systemic Neoplasms	10-161
Laboratory Examination Variables	10-178
Prostate-Specific Antigen (Continuous)	10-178
Prostate-Specific Antigen (Discrete)	10-187
Longitudinal Analysis	10-192
Verified Medical Records	10-193
Malignant Skin Neoplasms	10-193
Malignant Systemic Neoplasms	10-193
Benign Systemic Neoplasms	10-193
DISCUSSION	10-204
SUMMARY	10-204
Model 1.: Group Analysis	10-204
Model 2: Initial Dioxin Analysis	10-204
Model 3: Categorized Dioxin Analysis	10-223
Models 4, 5, and 6: Current Dioxin Analyses	10-224
CONCLUSION	10-224
REFERENCES	10-226

LIST OF TABLES

	Page
Table 10-1. Statistical Analyses for the Neoplasia Assessment	10-11
Table 10-2. Number of Participants with Missing Data for, or excluded from, the Neoplasia Assessment	10-15
Table 10-3. Analysis of Skin Neoplasms	10-22
Table 10-4. Analysis of Malignant Skin Neoplasms	10-27
Table 10-5. Analysis of Benign Skin Neoplasms	10-32
Table 10-6. Analysis of Skin Neoplasms of Uncertain Behavior or Unspecified Nature	10-37
Table 10-7. Analysis of Basal Cell Carcinomas (All Sites Combined)	10-41
Table 10-8. Analysis of Basal Cell Carcinomas (Ear, Face, Head, and Neck) . .	10-46
Table 10-9. Analysis of Basal Cell Carcinomas (Trunk)	10-51
Table 10-10. Analysis of Basal Cell Carcinomas (Upper Extremities)	10-55
Table 10-11. Analysis of Basal Cell Carcinomas (Lower Extremities)	10-60
Table 10-12. Analysis of Squamous Cell Carcinomas	10-64
Table 10-13. Analysis of Nonmelanomas	10-69
Table 10-14. Analysis of Melanomas	10-74
Table 10-15. Analysis of Systemic Neoplasms	10-78
Table 10-16. Analysis of Malignant Systemic Neoplasms	10-83
Table 10-17. Analysis of Benign Systemic Neoplasms	10-87
Table 10-18. Analysis of Systemic Neoplasms of Uncertain Behavior or Unspecified Nature	10-92
Table 10-19. Analysis of Malignant Systemic Neoplasms (Eye, Ear, Face, Head, and Neck)	10-96
Table 10-20. Analysis of Malignant Systemic Neoplasms (Oral Cavity, Pharynx, and Larynx)	10-101
Table 10-21. Analysis of Malignant Systemic Neoplasms (Esophagus)	10-105
Table 10-22. Analysis of Malignant Systemic Neoplasms (Brain)	10-107
Table 10-23. Analysis of Malignant Systemic Neoplasms (Thymus, Heart, and Mediastinum)	10-112
Table 10-24. Analysis of Malignant Systemic Neoplasms (Thyroid Gland)	10-116
Table 10-25. Analysis of Malignant Systemic Neoplasms (Bronchus and Lung) . .	10-120
Table 10-26. Analysis of Malignant Systemic Neoplasms (Colon and Rectum) . .	10-125
Table 10-27. Analysis of Malignant Systemic Neoplasms (Kidney and Bladder) ..	10-130
Table 10-28. Analysis of Malignant Systemic Neoplasms (Prostate)	10-134
Table 10-29. Analysis of Malignant Systemic Neoplasms (Testicles)	10-138
Table 10-30. Analysis of Malignant Systemic Neoplasms (Ill-Defined Sites) . .	10-143
Table 10-31. Analysis of Malignant Systemic Neoplasms (Connective and Other Soft Tissue)	10-147
Table 10-32. Analysis of Carcinomas in Situ of the Penis, Other, and Unspecified Sites	10-149

LIST OF TABLES (Continued)

	Page
Table 10-33. Analysis of Hodgkin's Disease	10-153
Table 10-34. Analysis of Leukemia	10-157
Table 10-35. Analysis of Non-Hodgkin's Lymphoma	10-162
Table 10-36. Analysis of Other Malignant Systemic Neoplasms of Lymphoid and Histiocytic Tissue	10-166
Table 10-37. Analysis of Multiple Myeloma	10-170
Table 10-38. Analysis of Skin or Systemic Neoplasms	10-174
Table 10-39. Analysis of Prostate-Specific Antigen (Below vs At or Above Sensitivity Limit)	1-179
Table 10-40. Analysis of Prostate-Specific Antigen (ng/ml) (Continuous)	10-183
Table 10-41. Analysis of Prostate-Specific Antigen (Discrete)	10-188
Table 10-42. Longitudinal analysis of Malignant Skin Neoplasms	10-194
Table 10-43. Longitudinal Analysis of Malignant Systemic Neoplasms	10-197
Table 10-44. Longitudinal Analysis of Benign Systemic Neoplasms	10-200
Table 10-45. Summary of Group Analyses (Model 1) for Neoplasia Variables (Ranch Hands vs Comparisons)	10-205
Table 10-46. Summary of Initial dioxin Analyses (Model 2) for Neoplasia Variables (Ranch Hands Only)	10-209
Table 10-47. Summary of Categorized Dioxin Analyses (Model 3) for Neoplasia Variables (Ranch Hands vs Comparisons)	10-211
Table 10-48. Summary of Current Dioxin Analyses (Models 4, 5, and 6) for Neoplasia Variables (Ranch Hands Only)	10-217
Table 10-49. Summary of Group-by-Covariate and Dioxin-by-Covariate Interactions from Adjusted Analyses of Neoplasia Variables	10-221

TABLE OF CONTENTS

	Page
CHAPTER 11 NEUROLOGICAL ASSESSMENT	11-1
INTRODUCTION	11-1
Background	11-1
Summary of Previous Analyses of the Air Force Health Study	11-3
1982 Baseline Study Summary Results	11-3
1985 Followup Study Summary Results	11-3
1987 Followup Study Summary Results	11-5
Parameters for the Neurological Assessment	11-6
Dependent Variables	11-6
Medical Records Data	11-6
Physical Examination Data	11-6
Covariates	11-8
Statistical Methods	11-9
Longitudinal Analyses	11-10
RESULTS	11-17
Dependent Variable-Covariate Associations	11-17
Age	11-17
Race	11-17
Occupation	11-18
Current Alcohol Use	11-18
Lifetime Alcohol History	11-18
Insecticide Exposure	11-18
Industrial Chemical Exposure	11-19
Degreasing Chemical Exposure	11-19
Diabetic Class	11-19
Serum Insulin	11-20
Composite Exposure to Heavy Metals	11-20
Worked with Vibrating Power Equipment or Tools	11-20
Exposure Analysis	11-20
Medical Records Variables: Historical Neurological Disorders	11-21
Inflammatory Diseases	11-21
Hereditary and Degenerative Diseases	11-22
Peripheral Disorders	11-31
Other Neurological Disorders	11-36
Physical Examination Variables: Cranial Nerve Function	11-41
Smell	11-41
Visual Fields	11-41
Light Reaction	11-50
Ocular Movement	11-55

TABLE OF CONTENTS (Continued)

	Page
Facial Sensation	11-55
Jaw Clench	11-64
Smile	11-64
Palpebral Fissure	11-71
Balance	11-71
Gag Reflex	11-71
Speech	11-71
Palate and Uvula Movement	11-87
Neck Range of Motion	11-87
Cranial Nerve Index without Range of Motion	11-94
Physical Examination Variables: Peripheral Nerve Status	11-99
Pin Prick	11-99
Light Touch	11-99
Muscle Status	11-108
Patellar Reflex	11-108
Achilles Reflex	11-118
Babinski Reflex	11-123
Vibrotactile Threshold Measurement of Right Great Toe	11-132
Vibrotactile Threshold Measurement of Left Great Toe	11-137
Physical Examination Variables: CNS Coordination Processes	11-142
Tremor	11-142
Coordination	11-147
Romberg Sign	11-147
Gait	11-156
Central Nervous System (CNS) Index	11-156
Longitudinal Analysis	11-165
Physical Examination Variables	11-165
Cranial Nerve Index without Range of Motion	11-165
CNS Index	11-166
DISCUSSION	11-166
SUMMARY	11-173
Medical Records	11-189
Model 1: Group Analysis	11-189
Model 2: Initial Dioxin Analysis	11-189
Model 3: Categorized Dioxin Analysis	11-189
Models 4 through 6: Current Dioxin Analysis	11-189
Physical Examination Variables	11-190
Model 1: Group Analysis	11-190
Model 2: Initial Dioxin Analysis	11-191
Model 3: Categorized Dioxin Analysis	11-191

TABLE OF CONTENTS (Continued)

	Page
Models 4 through 6: Current Dioxin Analyses11-191
CONCLUSION	11-191
REFERENCES	11-194

LIST OF TABLES

	Page
Table 11-1. Statistical Analyses for the Neurological Assessment	11-11
Table 11-2. Number of Participants with Missing Data for, or Excluded from, the Neurology Assessment	11-15
Table 11-3. Analysis of Inflammatory Diseases	11-23
Table 11-4. Analysis of Hereditary and Degenerative Diseases	11-27
Table 11-5. Analysis of Peripheral Disorders	11-32
Table 11-6. Analysis of Other Neurological Disorders	11-37
Table 11-7. Analysis of Smell	11-42
Table 11-8. Analysis of Visual Fields	11-46
Table 11-9. Analysis of Light Reaction	11-51
Table 11-10. Analysis of Ocular Movement	11-56
Table 11-11. Analysis of Facial Sensation	11-60
Table 11-12. Analysis of Jaw Clench	11-65
Table 11-13. Analysis of Smile	11-67
Table 11-14. Analysis of Palpebral Fissure	11-72
Table 11-15. Analysis of Balance	11-76
Table 11-16. Analysis of Gag Reflex	11-80
Table 11-17. Analysis of Speech	11-83
Table 11-18. Analysis of Palate and Uvula Movement	11-88
Table 11-19. Analysis of Neck Range of Motion	11-90
Table 11-20. Analysis of Cranial Nerve Index without Range of Motion	11-95
Table 11-21. Analysis of Pin Prick	11-100
Table 11-22. Analysis of Light Touch	11-104
Table 11-23. Analysis of Muscle Status	11-109
Table 11-24. Analysis of Patellar Reflex	11-114
Table 11-25. Analysis of Achilles Reflex	11-119
Table 11-26. Analysis of Biceps Reflex	11-124
Table 11-27. Analysis of Babinski Reflex	11-128
Table 11-28. Analysis of Vibrotactile Threshold Measurement of Right Great Toe (microns)	11-133
Table 11-29. Analysis of Vibrotactile Threshold Measurement of Left Great Toe (microns)	11-138
Table 11-30. Analysis of Tremor	11-143
Table 11-31. Analysis of Coordination	11-148
Table 11-32. Analysis of Romberg Sign	11-152
Table 11-33. Analysis of Gait	11-157
Table 11-34. Analysis of Central Nervous System (CNS) Index	11-161
Table 11-35. Longitudinal Analysis of Cranial Nerve Index without Range of Motion	11-167
Table 11-36. Longitudinal Analysis of Central Nervous System Index	11-170

LIST OF TABLES (Continued)

	Page
Table 11-37. Summary of Group Analyses (Model 1) for Neurological Variables (Ranch Hands vs Comparisons	11-174
Table 11-38. Summary of Initial Dioxin Analyses (Model 2) for Neurological Variables (Ranch Hands Only)	11-178
Table 11-39. Summary of Categorized Dioxin Analyses (Model 3) for Neurological Variables (Ranch Hands vs Comparisons)	11-180
Table 11-40. Summary of Current Dioxin Analyses (Models 4, 5, and 6) for Neurological Variables (Ranch Hands Only)	11-184
Table 11-41. Summary of Group-by-Covariate and Dioxin-by-Covariate Interactions from adjusted analyses of Neurological Variables	11-188

TABLE OF CONTENTS - REPORT

VOLUME I	EXECUTIVE SUMMARY ACKNOWLEDGEMENTS CHAPTER 1 - Introduction CHAPTER 2 - The Dioxin Assay CHAPTER 3 - Questionnaire Methodology CHAPTER 4 - Physical examination Methodology CHAPTER 5 - Study Selection and Participation CHAPTER 6 - Quality Control CHAPTER 7 - Statistical Methods CHAPTER 8 - Covariate Associations with Estimates of Dioxin Exposure CHAPTER 9 - General Health Assessment
VOLUME II	CHAPTER 10 - Neoplasia Assessment CHAPTER 11 - Neurological Assessment
VOLUME III	CHAPTER 12 - Psychological Assessment CHAPTER 13 - Gastrointestinal Assessment
VOLUME IV	CHAPTER 14 - Dermatologic Assessment CHAPTER 15 - Cardiovascular Assessment CHAPTER 16 - Hematologic Assessment
VOLUME V	CHAPTER 17 - Renal Assessment CHAPTER 18 - Endocrine Assessment
VOLUME VI	CHAPTER 19 - Immunologic Assessment CHAPTER 20 - Pulmonary Assessment CHAPTER 21 - Conclusions CHAPTER 22 - Future Directions
VOLUME VII	APPENDIX A - 1 through F-2
VOLUME VIII	APPENDIX G - 1 through I-4
VOLUME IX	APPENDIX J - 1 through N-4
VOLUME X	APPENDIX O - 1 through R